1[1]Kremer JM.Rational use of new and existing disease-modifying agents in rheumatoid arthritis.Ann Intern Med,2001,134(8):695-706.
2[2]Miceli-Richard C,Dougados M.Leflunomide for the treatment of rheumatoid arthritis.Expert Opin Pharmacother,2003,4(6):987-997.
3[3]Elkayam O,Yaron I,Shirazi I,et al.Active leflunomide metabolite inhibits interleukin 1beta,tumour necrosis factor alpha,nitric oxide,and metalloproteinase-3 production in activated human synovial tissue cultures.Ann Rheum Dis,2003,62(5):440-443.
4[4]Combe B,Eliaou JF,Daures JP,et al.Prognostic factors in rheumatoid arthritis.Comparative study of two subsets of patients according to severity of articular damage.Br J Rheumatol,1995,34(6):529-534.
5[5]Smolen JS,Kalden JR,Scott DL.Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis:a double-blind,randomized,multicentre trial.Lancet,1999,23(1):259-266.
6[6]Smolen JS.Efficacy and safety of the new DMARD leflunomide:comparison to placebo and sulfasalazine in active rheumatoid arthritis.Scand J Rheumatol Suppl,1999,112(1):15-21.
7[7]Osiri M,Shea B,Robinson V,et al.Leflunomide for treatment of rheumatoid arthritis:a systematic review and metaanalysis.J Rheumatol,2003,30(6):1182-1190.
10Egsmose C, Lund B, Borg G, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5-year followup of a prospective double blind controlled study [J]. J Rbeumatol, 1995, 22(12) :2208-2213.
